Cancer stage and consideration of cannabis use among adult cancer survivors in Southern California.

Nasim Kasiri, Matthew Banegas, Jesse Nodora, Maria Elena Martinez, David Strong, Neal Doran, Corinne McDaniels-Davidson, Humberto Parada
{"title":"Cancer stage and consideration of cannabis use among adult cancer survivors in Southern California.","authors":"Nasim Kasiri, Matthew Banegas, Jesse Nodora, Maria Elena Martinez, David Strong, Neal Doran, Corinne McDaniels-Davidson, Humberto Parada","doi":"10.1093/jncimonographs/lgad028","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The benefits of cannabis in symptom management among cancer survivors are widely acknowledged; however, patterns of cannabis use by cancer stage at diagnosis are unknown.</p><p><strong>Methods: </strong>Here, we examined the association between cancer stage at diagnosis and consideration of cannabis use since diagnosis. We analyzed cross-sectional survey data from 954 cancer survivors, weighted to be representative of a National Cancer Institute-Designated Comprehensive Cancer Center's patient population. We used survey-weighted multivariable logistic regression to examine the association between cancer stage at diagnosis (advanced [III/IV] versus non-advanced [I/II]) and consideration of cannabis use (yes versus no) since diagnosis.</p><p><strong>Results: </strong>Sixty percent of the population was diagnosed with non-advanced stages of cancer, and 42% had considered using cannabis since diagnosis. The odds of consideration of cannabis use were 63% higher (odds ratio = 1.63, 95% confidence interval = 1.06 to 2.49) among cancer survivors diagnosed at stages III/IV than among those diagnosed at stages I/II.</p><p><strong>Conclusion: </strong>Cancer stage may be a predictor of consideration of cannabis use after diagnosis.</p>","PeriodicalId":73988,"journal":{"name":"Journal of the National Cancer Institute. Monographs","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11303857/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Cancer Institute. Monographs","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jncimonographs/lgad028","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The benefits of cannabis in symptom management among cancer survivors are widely acknowledged; however, patterns of cannabis use by cancer stage at diagnosis are unknown.

Methods: Here, we examined the association between cancer stage at diagnosis and consideration of cannabis use since diagnosis. We analyzed cross-sectional survey data from 954 cancer survivors, weighted to be representative of a National Cancer Institute-Designated Comprehensive Cancer Center's patient population. We used survey-weighted multivariable logistic regression to examine the association between cancer stage at diagnosis (advanced [III/IV] versus non-advanced [I/II]) and consideration of cannabis use (yes versus no) since diagnosis.

Results: Sixty percent of the population was diagnosed with non-advanced stages of cancer, and 42% had considered using cannabis since diagnosis. The odds of consideration of cannabis use were 63% higher (odds ratio = 1.63, 95% confidence interval = 1.06 to 2.49) among cancer survivors diagnosed at stages III/IV than among those diagnosed at stages I/II.

Conclusion: Cancer stage may be a predictor of consideration of cannabis use after diagnosis.

南加州成年癌症幸存者的癌症阶段和使用大麻的考虑。
背景:方法:在此,我们研究了癌症确诊阶段与确诊后考虑使用大麻之间的关联。我们对 954 名癌症幸存者的横断面调查数据进行了分析,这些数据经过加权处理,能够代表国家癌症研究所指定的综合癌症中心的患者群体。我们使用调查加权多变量逻辑回归法研究了癌症诊断分期(晚期 [III/IV] 与非晚期 [I/II])与诊断后考虑使用大麻(是与否)之间的关联:结果:60%的人被诊断为非晚期癌症,42%的人在确诊后考虑过使用大麻。诊断为 III/IV 期的癌症幸存者考虑使用大麻的几率比诊断为 I/II 期的癌症幸存者高 63%(几率比 = 1.63,95% 置信区间 = 1.06 至 2.49):结论:癌症分期可能是确诊后考虑使用大麻的一个预测因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.30
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信